Valuation: SANOFI

Market Cap 87.03B 98.83B 82.46B 74.44B 140B 9,476B 142B 987B 380B 4,844B 371B 363B 15,531B P/E 2026 *
11.6x
P/E 2027 * 10.1x
Enterprise Value 98.49B 112B 93.32B 84.25B 159B 10,724B 161B 1,116B 430B 5,482B 420B 411B 17,577B EV / Sales 2026 *
2.07x
EV / Sales 2027 * 1.88x
Free-Float
88.34%
Yield 2026 *
5.86%
Yield 2027 * 6.19%
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer - 01/09/2026
Director TitleAgeSince
Director/Board Member 61 30/04/2019
Director/Board Member 56 28/04/2020
Director/Board Member 65 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 98.83B
-2.33%+0.53%+51.65%+115.42% 1,031B
-1.06%-1.65%+42.78%+69.98% 638B
-0.65%-1.32%+12.98%+75.49% 462B
-2.66%-1.87%+73.13%+41.15% 359B
-0.06%-3.88%+34.32%+39.39% 335B
-0.79%+2.01%+19.82%+27.79% 273B
-1.19%-1.21%+9.82%+10.61% 253B
-0.50%+3.80%+49.37%+56.84% 228B
-1.47%-1.53%+34.28%+98.89% 185B
Average -0.76%-0.18%+36.46%+59.51% 418.21B
Weighted average by Cap. -0.99%-0.23%+39.79%+71.21%

Financials

2026 *2027 *
Net sales 47.65B 54.11B 45.15B 40.76B 76.82B 5,188B 77.81B 540B 208B 2,652B 203B 199B 8,503B 50.64B 57.51B 47.98B 43.32B 81.65B 5,514B 82.7B 574B 221B 2,819B 216B 211B 9,038B
Net income 7.48B 8.49B 7.09B 6.4B 12.06B 814B 12.21B 84.78B 32.62B 416B 31.89B 31.19B 1,335B 8.89B 10.09B 8.42B 7.6B 14.33B 968B 14.51B 101B 38.76B 495B 37.89B 37.06B 1,586B
Net Debt 11.46B 13.02B 10.86B 9.81B 18.48B 1,248B 18.72B 130B 50.01B 638B 48.88B 47.81B 2,046B 8.34B 9.47B 7.9B 7.13B 13.44B 908B 13.61B 94.49B 36.36B 464B 35.55B 34.77B 1,488B
Logo SANOFI
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A